BMRA
Biomerica Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Biomerica Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
31.00%
of BMRA revenue · Undisclosed distributor customer
—
Expected move
No implied move.
—
No changes.
No changes.
No thesis.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Annual filing, covered
10-K parsed · Aug 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Aug 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Biomerica Inc
1.70
pre 1.67 −1.76%
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; no measured co-movers for Biomerica Inc.
Same SIC code · 6
Same SEC industry code: Idexx Laboratories Inc, Lantheus Holdings, Inc., Celldex Therapeutics, Inc. and 3 more; no measured co-movers for Biomerica Inc.
—
—
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $46,000 | 20.91% | new |
| Geodeindex-like | $42,857 | 19.48% | −56.56% |
| BlackRockindex-like | $32,799 | 14.91% | 0.00% |
| Vanguardindex-like | $25,545 | 11.61% | 0.00% |
| Jane Street | $22,246 | 10.11% | new |
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $46,000 | 20.91% | new |
| Geodeindex-like | $42,857 | 19.48% | −56.56% |
| BlackRockindex-like | $32,799 | 14.91% | 0.00% |
| Vanguardindex-like | $25,545 | 11.61% | 0.00% |
| Jane Street | $22,246 | 10.11% | new |
−23.17%
shares held · 10 largest managers